ABSTRACT
Antigens encoded by MAGE genes and recognized by T cells are of interest for cancer immunotherapy because of their strict tumoral specificity and because they are shared by many tumors. Several MAGE-1 peptide that are recognized by CD8(+) cytolytic T lymphocytes have been used in therapeutic vaccination trials. To obtain anti-tumor immune response, vaccines combining peptides recognized by CD8(+) and peptides recognized by CD4(+) T cells might be optimal. We focused therefore on the identification of MAGE peptides recognized by CD4(+) T cells. We report here the identification of MAGE-1 epitope EYVIKVSARVRF, which is presented to CD4(+) T lymphocytes by HLA-DR15. This HLA allele is present in 29 % of Asians and 17 % of Caucasians.
Subject(s)
CD4-Positive T-Lymphocytes/immunology , HLA-DR Antigens/immunology , Neoplasm Proteins/immunology , Antigen Presentation/immunology , Antigens, Neoplasm , Cell Line, Transformed , HLA-DR Serological Subtypes , Humans , Melanoma-Specific Antigens , Neoplasm Proteins/genetics , Peptides/immunology , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Tumor Cells, CulturedABSTRACT
Antigens encoded by MAGE-A3 and recognized by T cells are interesting targets for tumor immunotherapy because they are strictly tumor specific and shared by many tumors of various histological types. A number of MAGE-A3 antigenic peptides presented by HLA class I molecules have been used in clinical trials, and regressions of melanoma metastasis have been observed. We report here the identification of a MAGE-A3 epitope, TQHFVQENYLEY, presented to CD4+ T lymphocytes by HLA-DP4 molecules, which are expressed in approximately 76% of Caucasians. This new epitope may be useful both for therapeutic vaccination and for the evaluation of the immune response in cancer patients. Interest ingly, the CD4+ T cells lysed HLA-DP4 tumor cells expressing MAGE-A3, indicating that this epitope, in contrast to other class-II MAGE-A3 epitopes, is presented at the surface of tumor cells. The study of this disparity in the presentation of two epitopes from the same protein may lead to a better understanding of the endogenous class II presentation pathway.
Subject(s)
Antigen Presentation/immunology , Antigens, Neoplasm/immunology , CD4-Positive T-Lymphocytes/immunology , Epitopes, T-Lymphocyte/immunology , HLA-DP Antigens/immunology , Neoplasm Proteins , T-Lymphocytes, Cytotoxic/immunology , Animals , Baculoviridae/genetics , Clone Cells , Dendritic Cells/immunology , Escherichia coli/genetics , Escherichia coli/metabolism , HLA-DP beta-Chains , Humans , Melanoma/immunology , Spodoptera/metabolism , Spodoptera/virology , Tumor Cells, CulturedABSTRACT
The MAGE-A genes are expressed in tumor cells but not in healthy tissues, except in male germ line cells and in placenta. They encode tumor-specific antigens recognized by autologous cytolytic T lymphocytes (CTLs). On the basis of semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) assays, 6 of the 12 members of the MAGE-A family, including MAGE-A1, were previously reported to have a high level of expression in tumors, whereas 5 other members, including MAGE-A10, were expressed at a much lower level, deemed to be insufficient for CTL recognition. However, analysis with antibodies has shown that some melanoma cell lines contain equivalent amounts of MAGE-A1 and MAGE-A10 proteins. This discrepancy appeared to be due to the low efficacy of the primers that had been used for the previous MAGE-A10 RT-PCR assays. This led us to develop a method that is independent of the efficacy of the PCR primers to evaluate MAGE-A gene expression. cDNA libraries from tumor cell lines were introduced into bacteria, of which 200 pools of about 500 bacteria were maintained in microcultures. The frequencies of the MAGE-A cDNA clones in each library were evaluated by performing PCR assays on each of these pools. The abundance of MAGE-A10 cDNAs was found to be similar to that of MAGE-A1 in 3 of the libraries that were analyzed, including 2 with high expression (1/6,400), confirming that MAGE-A10 is expressed at a high level. MAGE-A2, A3, A4, A6 and A12 cDNAs were also confirmed often to be present at a frequency of more than 1/10,000, a level of expression that should suffice for recognition of antigenic peptides encoded by these genes by cytolytic T cells. The remaining MAGE genes are either not expressed in tumors or are expressed at a very low level, with the exception of MAGE-A8 and 11, which show high expression in a very small number of tumors. This method also allowed us to isolate 5 MAGE-A cDNAs that we had not obtained previously, enabling us to delineate the exons in the sequences of genes MAGE-A5, A8, A9, A10 and A11.
Subject(s)
Antigens, Neoplasm/genetics , Gene Expression Regulation, Neoplastic , Gene Library , Neoplasm Proteins/genetics , Antigens, Neoplasm/isolation & purification , Antigens, Neoplasm/metabolism , Chromosome Mapping , Humans , Male , Melanoma-Specific Antigens , Neoplasm Proteins/isolation & purification , Neoplasm Proteins/metabolism , Placenta/metabolism , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Testis/metabolism , Tumor Cells, CulturedABSTRACT
A subset of male germ line-specific genes, the MAGE-type genes, are activated in many human tumors, where they produce tumor-specific antigens recognized by cytolytic T lymphocytes. Previous studies on gene MAGE-A1 indicated that transcription factors regulating its expression are present in all tumor cell lines whether or not they express the gene. The analysis of two CpG sites located in the promoter showed a strong correlation between expression and demethylation. It was also shown that MAGE-A1 transcription was induced in cell cultures treated with demethylating agent 5'-aza-2'-deoxycytidine. We have now analyzed all of the CpG sites within the 5' region of MAGE-A1 and show that for all of them, demethylation correlates with the transcription of the gene. We also show that the induction of MAGE-A1 with 5'-aza-2'-deoxycytidine is stable and that in all the cell clones it correlates with demethylation, indicating that demethylation is necessary and sufficient to produce expression. Conversely, transfection experiments with in vitro-methylated MAGE-A1 sequences indicated that heavy methylation suffices to stably repress the gene in cells containing the transcription factors required for expression. Most MAGE-type genes were found to have promoters with a high CpG content. Remarkably, although CpG-rich promoters are classically unmethylated in all normal tissues, those of MAGE-A1 and LAGE-1 were highly methylated in somatic tissues. In contrast, they were largely unmethylated in male germ cells. We conclude that MAGE-type genes belong to a unique subset of germ line-specific genes that use DNA methylation as a primary silencing mechanism.
Subject(s)
CpG Islands , DNA Methylation , Gene Expression Regulation, Neoplastic , Gene Silencing , Neoplasm Proteins/genetics , Promoter Regions, Genetic , Azacitidine/analogs & derivatives , Azacitidine/pharmacology , DNA, Neoplasm/genetics , Decitabine , Humans , Male , Spermatozoa , Testis , Tissue Distribution , Tumor Cells, CulturedABSTRACT
Reverse transcription-polymerase chain reaction (RT-PCR)-based assays detecting occult neoplastic cells are increasingly being used for the study of tumour dissemination and minimal residual disease. However, different methods are employed by various research groups and the results are heterogenous. We prospectively assessed the results from nine laboratories performing tyrosinase RT-PCR assays for the detection of melanoma cells on a series of blind samples. After complete analysis, the results were compared for sensitivity and specificity. All laboratories reported correct results for cDNA standards. Five laboratories attained acceptable specificity and a sensitivity detecting 10 cells in 10 ml of whole blood. Four laboratories had unacceptable specificity and/or sensitivity. This blind study highlights the difficulty of RT-PCR data interpretation and the need for quality assurance between laboratories. Measures to increase the reliability of RT-PCR assays are proposed, which have to be prospectively evaluated in future studies.
Subject(s)
Melanoma/diagnosis , Neoplastic Cells, Circulating , Polymerase Chain Reaction/standards , DNA, Neoplasm/analysis , Humans , Polymerase Chain Reaction/methods , Prospective Studies , RNA, Neoplasm/analysis , Sensitivity and SpecificityABSTRACT
In the past 10 years, much attention has been focused on transcription preinitiation complex formation as a target for regulating gene expression, and other targets such as transcription termination complex assemblage have been less intensively investigated. We established the existence of poly(A) site choice and fusion splicing of two adjacent genes, galactose-1-phosphate uridylyltransferase (GALT) and interleukin-11 receptor alpha-chain (IL-11Ralpha), in normal human cells. This 16-kilobase (kb) transcription unit contains two promoters (the first one is constitutive, and the second one, 8 kb downstream, is highly regulated) and two cleavage/polyadenylation signals separated by 12 kb. The promoter from the GALT gene yields two mRNAs, a 1.4-kb mRNA encoding GALT and a 3-kb fusion mRNA when the first poly(A) site is spliced out and the second poly(A) is used. The 3-kb mRNA codes for a fusion protein of unknown function, containing part of the GALT protein and the entire IL-11Ralpha protein. The GALT promoter/IL-11Ralpha poly(A) transcript results from leaky termination and alternative splicing. This feature of RNA polymerase (pol) II transcription, which contrasts with efficient RNA pol I and pol III termination, may be involved, together with chromosome rearrangements, in the generation of fusion proteins with multiple domains and would have major evolutionary implications in terms of natural processes to generate novel proteins with common motifs. Our results, together with accumulation of genomic informations, will stimulate new considerations and experiments in gene expression studies.
Subject(s)
Chromosomes, Human, Pair 9 , RNA Splicing , Receptors, Interleukin/genetics , UTP-Hexose-1-Phosphate Uridylyltransferase/genetics , Animals , COS Cells , Chromosome Mapping , Evolution, Molecular , Humans , Interleukin-11 Receptor alpha Subunit , Promoter Regions, Genetic , RNA, Messenger/metabolism , Receptors, Interleukin-11 , Transcription, GeneticABSTRACT
Representational difference analysis was used to identify genes that are expressed in a human melanoma cell line and not in normal skin. A cDNA clone that appeared to be specific for tumors was obtained and the corresponding gene was sequenced. This new gene was named LAGE-I. Using a LAGE-I probe to screen a cDNA library from the same melanoma cell line, we identified a closely related gene, which proved to be identical to NY-ESO-I, a gene recently reported to code for an antigen recognized by autologous antibodies in an esophageal squamous cell carcinoma. Gene LAGE-I maps to Xq28. It comprises 3 exons. Alternative splicing produces 2 major transcripts encoding polypeptides of 210 and 180 residues, respectively. Expression of LAGE-I was observed in 25-50% of tumor samples of melanomas, non-small-cell lung carcinomas, bladder, prostate and head and neck cancers. The only normal tissue that expressed the gene was testis. As for MAGE-AI, expression of LAGE-I is induced by deoxy-azacytidine in lymphoblastoid cells, suggesting that tumoral expression is due to demethylation. The expression of LAGE-I is strongly correlated with that of NY-ESO-I. It is also clearly correlated with the expression of MAGE genes.
Subject(s)
Antigens, Neoplasm , Membrane Proteins , Neoplasms/genetics , Oncogenes , Proteins/genetics , Amino Acid Sequence , Antigens, Surface , Base Sequence , Chromosome Mapping , Humans , Melanoma/genetics , Molecular Sequence Data , Tumor Cells, CulturedABSTRACT
Human genes expressed exclusively in tumors and male germ line cells, such as those of the MAGE, BAGE, and GAGE families, encode antigens recognized by T lymphocytes, which are potentially useful for antitumor immunotherapy. To identify new genes of this type, we generated cDNA populations enriched in sequences expressed only in testis and melanoma, using the representational difference analysis approach. A testis cDNA library enriched by subtraction with cDNA from four other normal tissues was hybridized with radiolabeled melanoma cDNA enriched by subtraction with normal skin cDNA. A cDNA fragment sharing significant homology with MAGE genes was identified, and a cosmid containing this new gene, named MAGE-C1, was isolated. MAGE-C1 is composed of four exons and encodes a putative protein of 1142 amino acids. It is about 800 residues longer than the other MAGE proteins due to the insertion of a large number of short repetitive sequences in front of the MAGE-homologous sequence. The MAGE-C1 gene appears to be located on band Xq26, whereas the MAGE-A and MAGE-B genes are located on Xq28 and Xp21, respectively. Like other MAGE genes, MAGE-C1 is expressed in a significant proportion of tumors of various histological types, whereas it is silent in normal tissues except testis. It is probable, therefore, that like other MAGE genes, MAGE-C1 encodes antigens that may constitute useful targets for cancer immunotherapy because of their strict tumoral specificity.
Subject(s)
Antigens, Neoplasm/immunology , Melanoma/genetics , Neoplasm Proteins/genetics , Amino Acid Sequence , Base Sequence , DNA, Complementary , Gene Expression , Gene Library , Humans , Male , Molecular Sequence Data , Neoplasm Proteins/chemistry , Polymorphism, Genetic , Repetitive Sequences, Nucleic Acid , Sequence Alignment , Testis/metabolism , X ChromosomeABSTRACT
Human gene MAGE-1 codes for an antigen that is recognized on a melanoma by an autologous cytotoxic T lymphocyte (CTL). Because MAGE-1 is expressed on a significant proportion of tumours of various histological types and not on normal tissues, the encoded antigen may serve as a target for cancer immunotherapy. Evaluation of the expression of the gene by reverse transcription polymerase chain reaction (RT-PCR) in various tumour samples and tumour cell lines has suggested great variability in the level of expression. It was therefore important to evaluate the minimal level of expression required for lysis by CTL. We tested a number of melanoma cell lines by a quantitative RT-PCR assay to correlate their level of MAGE-1 expression and recognition by the relevant CTL clone. We found that only cell lines expressing more than 10% of the MAGE-1 messenger RNA (mRNA) level of reference cell line MZ2-MEL.3.0 (i.e. more than three mRNA molecules per cell) were lysed by the CTL or induced significant tumour necrosis factor release.
Subject(s)
Antigens, Neoplasm/biosynthesis , Antigens, Neoplasm/immunology , Melanoma/immunology , Melanoma/metabolism , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/immunology , RNA, Messenger/metabolism , T-Lymphocytes, Cytotoxic/immunology , Cytotoxicity, Immunologic , HLA-A1 Antigen/immunology , Humans , Melanoma-Specific Antigens , Polymerase Chain Reaction , Sensitivity and Specificity , Transcription, Genetic , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/biosynthesisABSTRACT
Strategies have been developed to characterize tumor antigens recognized by cytolytic T lymphocytes (CTL). We use a genetic approach based on the transfection of HLA genes and cDNA libraries in COS cells to isolate the gene producing the antigenic peptide. The tumor-specific expression of this gene can be evaluated by cDNA synthesis and quantitative PCR amplification. Transfection of fragments of the isolated gene allows the identification of the region encoding the antigenic peptide. Peptides are synthesized and tested for their ability to sensitize target cells to lysis by the CTL.
Subject(s)
Antigens, Neoplasm/genetics , Gene Expression Regulation, Neoplastic/genetics , HLA Antigens/genetics , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Animals , Antigens, Neoplasm/immunology , Base Sequence , COS Cells , Cloning, Molecular , HLA Antigens/immunology , Humans , Molecular Sequence Data , Polymerase Chain Reaction , TransfectionABSTRACT
Melanoma lines MEL.A and MEL.B were derived from metastases removed from patient LB33 in 1988 and 1993, respectively. The MEL.A cells express several antigens recognized by autologous cytolytic T lymphocytes (CTL) on HLA class I molecules. The MEL.B cells have lost expression of all class I molecules except for HLA-A24. By stimulating autologous lymphocytes with MEL.B, we obtained an HLA-A24-restricted CTL clone that lysed these cells. A novel gene, PRAME, encodes the antigen. It is expressed in a large proportion of tumors and also in some normal tissues, albeit at a lower level. Surprisingly, the CTL failed to lyse MEL.A, even though these cells expressed the gene PRAME. The CTL expresses an NK inhibitory receptor that inhibits its lytic activity upon interaction with HLA-Cw7 molecules, which are present on MEL.A cells and not on MEL.B. Such CTL, active against tumor cells showing partial HLA loss, may constitute an intermediate line of anti-tumor defense between the CTL, which recognize highly specific tumor antigens, and the NK cells, which recognize HLA loss variants.
Subject(s)
Antigens, Neoplasm/immunology , HLA Antigens/biosynthesis , HLA Antigens/immunology , Killer Cells, Natural/metabolism , Melanoma/immunology , Receptors, Immunologic/biosynthesis , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/metabolism , Amino Acid Sequence , Base Sequence , Humans , Molecular Sequence Data , Receptors, KIR , Tumor Cells, CulturedABSTRACT
Tumor antigen P815AB is recognized by cytolytic T lymphocytes (CTL) on mouse mastocytoma P815. This antigen is encoded by P1A, a gene activated in several tumors but silent in normal tissues except for testis and placenta. Notwithstanding the expression of P1A in testis, we found that male mice mounted P815AB-specific CTL responses as efficiently as females. The responding males remained fertile and no autoimmune lesions were observed in their testes. By immunohistochemistry with a rabbit antiserum directed against the P1A protein, we identified spermatogonia as the testicular cells expressing P1A. The absence of MHC class-I molecules on spermatogonia could be one of the mechanisms of protection against testicular autoimmunity, as the antigenic peptide should not be displayed at the cell surface. Human genes MAGE, BAGE and GAGE, which also code for tumor antigens recognized by autologous CTL, are not expressed in normal tissues other than testis. The results obtained in mice with antigen P815AB suggest that immunization of human males with such antigens will not generate autoimmune side-effects. Although P1A is strongly expressed in placenta, we also found that gestation did not prevent generation of CTL responses against antigen P815AB, and that such CTL responses did not affect gestation outcome. We identified labyrinthine trophoblasts as the placental cells expressing P1A. Again, the absence of MHC class-I molecules on these cells provides a plausible explanation for placental protection, although other mechanisms may also play a role.
Subject(s)
Antigens, Neoplasm/immunology , Mast-Cell Sarcoma/immunology , Spermatogonia/immunology , T-Lymphocytes, Cytotoxic/immunology , Testis/immunology , Animals , Antigens, Neoplasm/genetics , Antigens, Neoplasm/metabolism , Female , Leukemia L1210/immunology , Male , Mice , Mice, Inbred DBA , Placenta/immunology , Polymerase Chain Reaction , Pregnancy , Sex Factors , Specific Pathogen-Free Organisms , Testis/metabolismABSTRACT
Anti-melanoma cytolytic T-lymphocyte (CTL) clones were derived from peripheral blood lymphocytes of HLA-A2 melanoma patient LB265 after stimulation with the autologous tumor cell line LB265-MEL, which showed high expression of melanocyte-lineage specific genes. Of 55 CTL clones, 46 recognized HLA-A2-restricted antigens. These 46 CTL clones were studied for their ability to specifically release tumor necrosis factor in the presence of COS cells cotransfected with the HLA-A2 gene and the cDNA of either tyrosinase, Melan-A/MART1, Pmel17/gpl00, gp75/TRP1, or MSH receptor. Six CTL clones recognized the Melan-A/MART1 antigen, whereas the remaining 40 CTL clones recognized a Pmel17/gp100 antigen. These 40 anti-PmelI7/gpl00 CTL clones were all able to lyse T2 cells pulsed with the antigenic peptide YLEPGPVTA, as previously reported. The T-cell receptor beta chain hypervariable region was sequenced and found to be identical in the 15 CTL clones analyzed. Taken together, these data show a high frequency of Pmell7/gp100-specific T cells in autologous antitumor CTL clones derived from peripheral blood of a melanoma patient.
Subject(s)
Antigens, Neoplasm/immunology , Genes , HLA-A2 Antigen/genetics , Melanoma/immunology , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Base Sequence , Clone Cells , Female , Humans , Melanoma/blood , Molecular Sequence Data , Oligonucleotide Probes/genetics , Receptors, Antigen, T-Cell, alpha-beta/geneticsABSTRACT
A cytolytic T lymphocyte (CTL) clone that lyses many HLA-A2 melanomas was derived from a population of tumor-infiltrating lymphocytes of an HLA-A2 melanoma patient. The gene coding for the antigen recognized by this CTL was identified by transfection of a cDNA library. It is the gene which has been reported to code for N-acetylglucosaminyltransferase V (GnT-V). Remarkably, the antigenic peptide recognized by the CTL is encoded by a sequence located in an intron. In contrast to the fully spliced GnT-V mRNA, which was found in a wide range of normal and tumoral tissues, the mRNA containing the intron region coding for the antigen was not found at a significant level in normal tissues. This mRNA was observed to be present in about 50% of melanomas. Our results suggest that a promoter located near the end of the relevant intron is activated in melanoma cells, resulting in the production of an mRNA coding for the antigen.
Subject(s)
Antigens, Neoplasm/genetics , HLA-A2 Antigen/immunology , Introns , Lymphocytes, Tumor-Infiltrating/immunology , Melanoma/genetics , Melanoma/immunology , N-Acetylglucosaminyltransferases/genetics , Neoplasms/genetics , Neoplasms/immunology , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Antigens, Neoplasm/biosynthesis , Base Sequence , Coculture Techniques , Cytotoxicity, Immunologic , DNA Primers , DNA, Complementary , Female , Gene Expression , Gene Library , Humans , Male , Melanoma/enzymology , Molecular Sequence Data , Neoplasms/enzymology , Polymerase Chain Reaction , RNA, Messenger/analysis , RNA, Messenger/biosynthesis , Random Amplified Polymorphic DNA Technique , Restriction Mapping , Transfection , Tumor Cells, CulturedABSTRACT
The human tyrosinase gene has been reported previously to code for two distinct antigens recognized on HLA-A2 melanoma cells by autologous cytolytic T lymphocytes (CTL). By stimulating lymphocytes of melanoma patient MZ2 with a subclone of the tumor cell line of this patient, we obtained a CTL clone that lysed this subclone but did not lyse other subclones of the same melanoma cell line. The sensitive melanoma subclone was found to express a much higher level of tyrosinase than the others, suggesting that the antigen recognized by the CTL might be encoded by tyrosinase. Transfection of a tyrosinase cDNA demonstrated that the CTL clone indeed recognized a tyrosinase product presented by HLA-B*4403. The relevant antigenic peptide corresponds to residues 192-200 of the tyrosinase protein. Lymphoblastoid cells of the B*4402 subtype were not recognized by the CTL following incubation with the peptide. Nevertheless, by stimulating in vitro lymphocytes of a healthy HLA-B*4402 donor with autologous adherent cells pulsed with the same peptide, we obtained a CTL clone which recognized tumor cells expressing tyrosinase and HLA-B*4402. As HLA-B44 is expressed in 24% of Caucasians, the tyrosinase-B44 antigen may constitute a useful target for specific immunotherapy of melanoma.
Subject(s)
Antigen Presentation , HLA-B Antigens/immunology , Melanoma/immunology , Monophenol Monooxygenase/immunology , Oligopeptides/immunology , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Antigens, Neoplasm/genetics , Antigens, Neoplasm/immunology , Base Sequence , HLA-B Antigens/genetics , HLA-B44 Antigen , Humans , Melanoma/genetics , Molecular Sequence Data , Monophenol Monooxygenase/genetics , Oligopeptides/genetics , Tumor Cells, CulturedABSTRACT
Human genes MAGE-1 and MAGE-3 code for antigens that are recognized on melanoma cells by autologous cytolytic T lymphocytes. These antigens may constitute useful targets for specific anti-tumor immunization of cancer patients, since genes MAGE-1 and MAGE-3 are expressed in a number of tumors of different histological types, but are not expressed in normal adult tissues other than testis. This also applies to genes MAGE-2 and MAGE-4, which are closely related to MAGE-1 and MAGE-3. We have analyzed the expression of these 4 MAGE genes in cutaneous melanoma. Sixteen of 100 primary tumors vs. 69 (48%) of 145 metastases from individual patients expressed MAGE-1. Similar differences in the frequency of gene expression between primary and metastatic tumor samples were observed for MAGE-2, MAGE-3, and MAGE-4. MAGE expression in primary tumors was correlated with tumor thickness: there was a significantly increased frequency in the expression of MAGE-1, -2 and -3 in tumors of greater thickness. Benign and dysplastic nevi, as well as in situ melanomas, did not express any of the 4 MAGE genes.
Subject(s)
Antigens, Neoplasm/genetics , Melanoma/genetics , Neoplasm Proteins , Skin Neoplasms/genetics , Adult , Base Sequence , Gene Expression , Humans , Melanoma/pathology , Melanoma/secondary , Melanoma-Specific Antigens , Molecular Sequence Data , Skin Neoplasms/pathologyABSTRACT
We have identified an antigen recognized on a human melanoma by autologous cytolytic T lymphocytes. It is encoded by a gene that is expressed in many normal tissues. Remarkably, the sequence coding for the antigenic peptide is located across an exon-intron junction. A point mutation is present in the intron that generates an amino acid change that is essential for the recognition of the peptide by the anti-tumor cytotoxic T lymphocytes. This observation suggests that the T-cell-mediated surveillance of the integrity of the genome may extend to some intronic regions.
Subject(s)
Antigens, Neoplasm/immunology , Introns , Melanoma/immunology , Neoplasm Proteins/immunology , Point Mutation , T-Lymphocytes, Cytotoxic/immunology , Alleles , Amino Acid Sequence , Antigens, Neoplasm/genetics , Base Sequence , Binding, Competitive , Cell Line , Cloning, Molecular , Cytotoxicity, Immunologic , Exons , Humans , Kinetics , Molecular Sequence Data , Mutagenesis , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , Recombinant Proteins/immunology , Transfection , Tumor Cells, CulturedABSTRACT
Mouse mastocytoma P815 expresses tumor antigens P815A and P815B encoded by a single gene called P1A and carried by a single peptide named P1A 35-43 (NH2-Leu-Pro-Tyr-Leu-Gly-Trp-Leu-Val-Phe-COOH). P1A 35-43 is presented to anti-P815A and anti-P815B cytotoxic T lymphocytes (CTL) by major histocompatibility complex (MHC) H-2Ld molecules. In order to determine the individual role played by each amino acid residue of P1A 35-43 in binding to H-2Ld and in recognition by anti-A and anti-B T cell receptors (TcR), a series of P1A35-43 peptides substituted by alanine at single positions was synthesized and tested for binding to H-2Ld and for CTL recognition. Binding to H-2Ld was estimated by measuring the ability of the peptide to up-regulate cell surface expression of H-2Ld. We found that three residues were important for interaction of P1A 35-43 with H-2Ld. Two of them, Pro at position 2 and Phe at position 9 were consistent with the described H-2Ld binding motif. A third residue, Trp at position 6, was also required for effective MHC binding of the tumor antigen. CTL sensitization assays showed that alanine substitution at position 7 (Leu) or at position 8 (Val) dramatically affected peptide recognition by anti-A CTL while positions 3 (Tyr) and 4 (Leu) were critical for recognition by anti-B CTL. We conclude that Pro2, Trp6 and Phe9 constitute the anchor residues of P1A 35-43 to H-2Ld, whereas the dipeptidyl sequences Tyr3-Leu4 and Leu7-Val8 form the core epitopes recognized by the TcR of anti-P815B and anti-P815A CTL, respectively.
Subject(s)
Antigens, Neoplasm/immunology , Epitopes , H-2 Antigens/immunology , Mast-Cell Sarcoma/immunology , Peptide Fragments/immunology , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Animals , Antigens, Neoplasm/genetics , Histocompatibility Antigen H-2D , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Tumor Cells, CulturedABSTRACT
Human gene MAGE-I codes for an antigen that is recognized on melanoma cells by autologous cytolytic T lymphocytes (CTL). This antigen is potentially useful as a target for cancer immunotherapy because gene MAGE-I is not expressed in any normal tissues except the testis. We tested 46 surgical samples of non-small-cell lung carcinomas and observed MAGE-I expression in 16 of them (35%). Genes MAGE-2 and 3, which are closely related to MAGE-I, were expressed by a similar proportion of these tumors. Some small-cell lung tumors also express MAGE genes. The proportion of tumors expressing MAGE-I suggests that lung tumor patients may constitute the largest group of patients potentially eligible for pilot studies involving MAGE-I immunization.